Recent Updates
Recently added Catalysts
CVRX Negative Sentiment Score: 20/100

CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Key Takeaway: Bronstein, Gewirtz & Grossman, LLC is conducting an investigation into CVRx, Inc. regarding potential wrongdoings that may have affected investors. This follows a report from the Centers for Medicare and Medicaid Services proposing substantial cuts to reimbursement rates for CVRx's heart failure device. Specifically, rates are expected to decrease by 38.1% for Ambulatory Surgical Center services and 32.9% for hospital outpatient services, resulting in a significant drop in CVRx's stock value. The investigation invites investors to share information related to their purchases of CVRx securities.

Market Sentiment Analysis

CONCERNS & RISKS

  • CVRx's heart failure device reimbursement rates are expected to drop significantly, leading to financial strain.
  • The company's shares fell over 38.5% following the announcement of the proposed payment rates, indicating a severe negative market reaction.

Full Press Release Details

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. (“CVRx” or “the Company”) (NASDAQ: CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/CVRX.
Investigation Details
On July 10, 2024, the Centers for Medicare and Medicaid Services (“CMS”) issued proposed payment rates for outpatient and Ambulatory Surgical Center (“ASC”) services. Piper Sandler issued a note indicating that under the CMS rules, reimbursement for CVRx’s heart failure device would fall by 38.1% for ASC services and by 32.9% for hospital outpatient services. Based on this news, shares of CVRx dropped over 38.5% on the same day.
If you are aware of any facts relating to this investigation or purchased CVRx securities, you can assist this investigation by visiting the firm’s site: bgandg.com/CVRX. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Tags

Frequently Asked Questions

What is the purpose of the CVRx investigation?

The investigation focuses on potential claims for investors who purchased CVRx securities.

Why did CVRx shares drop significantly?

CVRx shares fell over 38.5% following proposed CMS reimbursement rate cuts for its device.

Is there a cost to participate in the class action?

There is no cost; fees are contingent on a successful recovery in the lawsuit.

How can I assist the CVRx investigation?

You can provide information or learn more by visiting bgandg.com/CVRX.

What are the credentials of Bronstein, Gewirtz & Grossman?

The firm is nationally recognized for recovering funds in securities fraud class actions.

Last updated: Aug 19, 2024